Vivos Therapeutics (VVOS) Operating Leases (2021 - 2026)

Vivos Therapeutics (VVOS) has reported Operating Leases for 6 consecutive years, with $3.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Leases rose 22.17% year-over-year to $3.4 million in Q2 2026; TTM through Jun 2026 was $3.4 million, a 22.17% increase from a year earlier, with the FY2025 full-year figure at $3.8 million, up 271.01% from the prior year.
• Operating Leases was $3.4 million for Q2 2026 at Vivos Therapeutics, down from $3.7 million in the prior quarter.
• Over five years, Operating Leases peaked at $3.8 million in Q4 2025 and troughed at $932000.0 in Q1 2025.
• A 5-year average of $2.3 million and a median of $2.2 million in 2023 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases tumbled 50.48% in 2025 and soared 291.95% in 2026, its largest moves.
• Over 5 years, Operating Leases stood at $2.0 million in 2022, then decreased by 23.72% to $1.5 million in 2023, then plunged by 31.95% to $1.0 million in 2024, then surged by 271.01% to $3.8 million in 2025, then decreased by 10.47% to $3.4 million in 2026.
• The last three Operating Leases figures came in at $3.4 million (Q2 2026), $3.7 million (Q1 2026), and $3.8 million (Q4 2025), per Business Quant data.